Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

N-Acetyl Cysteine and Reduced Malondialdehyde

Doses used in studies

mg/day: 1,200–2,400 (median 1,800, IQR 1,500–2,100) — 2 studies

Time to effect

Median: 4.4 months · IQR 3.6 months–5.3 months · Range 2.8 months–6.1 months — Reported in 2 of 2 studies

Safety in these studies

Overall tolerabilityReported
Group 2 has substantial improvement in various metabolic parameters and health-related quality of life with accepted safety profile parameters.
from: New Approach Combination-Dosed Therapy for Nonalcoholic Steatohepatitis Versus Vitamin E:

2 of 2 papers

New Approach Combination-Dosed Therapy for Nonalcoholic Steatohepatitis Versus Vitamin E: A Randomized Controlled Trial.
- 2025-08
- RCT · n = 45
- Clinical therapeutics 47(8)
- - Amr Y Zakaria
  - Rehab Badawi
  - Hasnaa Osama
  - Mona A Abdelrahman
  - Asmaa M El-Kalaawy
- PubMed: 40480879
- DOI: 10.1016/j.clinthera.2025.05.006
13 Insights on
- Reduced Malondialdehyde
- High evidence
- Clinical
both groups reported significant reductions in mean values of ... 27.43% (P = 0.001), respectively
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
1200 mg twice daily
A Pilot Study to Evaluate the Effects of Oral N-Acetyl Cysteine on Inflammatory and Oxidative Stress Biomarkers in Rheumatoid Arthritis.
- 2019-07-31
- RCT · n = 23
- Current rheumatology reviews 15(3)
- - Ghazal Hashemi
  - Mahtabalsadat Mirjalili
  - Zahra Basiri
  - Ahmad Tahamoli-Roudsari
  - Nejat Kheiripour
  - Maryam Shahdoust
  - Akram Ranjbar
  - Maryam Mehrpooya
  - Sara Ataei
- PubMed: 30255760
- DOI: 10.2174/1573403x14666180926100811
10 Insights on
- Reduced Malondialdehyde
- High evidence
- Clinical
only NO, MDA and TTG showed a significant difference in the NAC group as compared to the placebo group at the end of study
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
600 mg twice daily